Burkitt lymphoma cells in 1964. Since then, EBV has been associated with a number of other malignancies of either lymphocytic origin, including both B cell and NK/T cell cancers, or epithelial origin, predominantly nasopharyngeal and gastric cancers. While a complete understanding of the relationship between EBV-mediated cellular transformation and the oncogenic events that lead to uncontrolled malignant cell growth remains to be determined for a number of these cancers, it is clear in all of these settings that a breakdown in the immune surveillance of virally infected cells contributes to the survival of EBV-bearing malignant cells.
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The lifecycle of EBV infection
As with most members of the Herpesvirus family, evolutionary adaptation over millions of years has allowed EBV to establish a unique biological niche in humans that allows it to maintain persistent infection for life with typically limited complications for the host and an efficient capacity to infect a new host. As a consequence of this efficient lifecycle, EBV is ubiquitous in the community, infecting 90-95% of the world population 1 Intermittent lytic replication in the upper respiratory tract promotes viral shedding and spread to a new host. This unique aspect of EBV biology, and that of the related gamma-herpesviruses, distinguishes it from other herpesviruses by promoting B cell proliferation without the need for active viral replication. However, it is also this capacity to efficiently transform B cells and induce lymphoproliferation, which leads to both the malignant and lymphoproliferative disorders, that are associated with EBV-infected cells [4] [5] [6] . A summary of common EBV-associated malignancies and their viral gene expression is shown in Table 1 .
Post-transplant lymphoproliferative disorders
Post-transplant lymphoproliferative disorders (PTLD) arise in immunocompromised patients who have undergone either solid organ (SOT) or haematopoietic stem cell transplantation (HSCT) and are almost universally associated with EBV infection 7 . Under normal immunological conditions EBV-infected B cells are controlled by EBV-specific cytotoxic T lymphocytes, which efficiently clear these cells predominantly via the recognition of peptide epitopes encoded by EBNA3-6 8 . However, the immunosuppressive environment associated with SOT and HSCT disrupts this immunological balance and can lead to uncontrolled proliferation of these EBV-infected cells that can typically be characterised with a latency III profile and the expression of the full array of latent genes 9 (Table 1) . PTLD in SOT patients is usually of recipient origin and is most prevalent in seronegative transplant recipients as a
In Focus consequence of primary infection following transplant of organs containing EBV-infected cells. However, PTLD can occur in seropositive recipients as a consequence of the immunosuppressive regime used to prevent organ rejection. In Australia, PTLD is typically diagnosed in 1-10% of SOT recipients and is more highly prevalent in children due to an increased likelihood of seronegative status prior to transplant 10 . PTLD in HSCT patients is usually of donor origin and is most prevalent in seropositive recipients who receive a transplant from a seronegative donor. This is typically facilitated by the reactivation of EBV of recipient origin and subsequent infection of B cells of donor origin and the concomitant immunosuppression of the induction of an EBV-specific cellular immune response. However, PTLD does occur following transplant from seropositive donors and increased risks are also associated with T cell depleted HSCT, commonly used to reduce the risk of graft-versus-host disease and due to HLA mismatch between donor and recipient 7 .
A reduction in the immunosuppressive regime is usually the first option for treatment of PTLD in both SOT and HSCT patients in order to restore/promote EBV-specific cellular immunity. Rituximab, an antibody that recognises CD20 on the surface of most B cells, is also used to treat PTLD in both SOT and HSCT patients, often in combination with standard chemotherapy used to treat other B cell lymphomas 11 . In addition, adoptive cellular therapy is emerging as a powerful tool for the treatment of EBV-associated PTLD, particularly in the context of HSCT. Pioneered by Rooney and colleagues at the Baylor College of Medicine in Texas, the transfer of EBV-specific T cells, which classically involves the use of in vitro-generated EBV-infected lymphoblastoid cell lines (LCL) to stimulate donor memory T cells, have been used effectively both therapeutically and prophylactically to treat or prevent PTLD in HSCT patients [12] [13] [14] . However, in the context of PTLD in SOT patients or following a seronegative HSCT transplant, the success of EBVspecific cellular therapy is dependent on the generation of recipient-derived T cells 15 (Table 1) . While this has been used successfully to resolve PTLD in SOT patients, an emerging approach for the treatment of PTLD in these instances is the use of a bank of thirdparty T cells [16] [17] [18] [19] . These T cells are generated from another EBVseropositive healthy donor who shares HLA alleles with the patient.
Initial reservations surrounding the potential risk of inducing graftversus-host disease or organ rejection have proven to be unfounded following the administration of third-party T cells and they have proven effective in the treatment of PTLD in both SOT and HSCT patients 7, 20 . In Focus subtype 21 . While associated with all HL subtypes, EBV infection is most prevalent in classical HL. EBV-infected Reed-Sternberg cells express a latency II gene expression pattern, which is restricted to EBNA1 and LMP1&2 (Table 1) The incidence of HL is bimodal in nature, with a peak in incidence in children under 10 years and in adults over 50 years. An increased risk of developing EBV-associated HL has also been linked to infectious mononucleosis during primary EBV infection 28 . HL is highly amenable to current chemotherapeutic regimes, with 5-year survival rates approaching 90%. However, EBV infection is associated with more rapid progression in HL patients and reduced overall survival 29 . The current chemotherapeutic regimes used to treat HL are also associated with an increased risk of the development of secondary cancers and strategies to reduce the dependence of the current level of chemotherapy are under development, particularly for children 30 . EBV-associated HL, often when refractory to chemotherapy, has also been successfully treated with adoptive cellular therapy 29, [31] [32] [33] [34] [35] [36] . While initial studies focussed on the LCL-based approach used to treat PTLD, more recent approaches have specifically targeted the induction of T cells specific for EBNA1 and LMP1&2 37 . These approaches have proved to be successful in phase 1 clinical studies and are currently being evaluated in phase II studies 31 .
EBV-associated Hodgkin and non-Hodgkin lymphomas
EBV infection is also associated with a number of non-Hodgkin's lymphomas (NHL), including Burkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL) 38 . Although rare in Australia, EBVassociated BL is endemic in regions of Africa and Papua New Guinea 22 . It arises primarily in young children and its incidence is closely associated with malaria endemic regions, which has been attributed to a loss of functionality in EBV-specific T cells in children with co-exposure to malaria 39, 40 . Burkitt lymphoma cells typically display an EBV latency I profile, characterised by the expression of only EBNA1 (Table 1 ). In association with reduced expression of surface HLA molecules, this renders BL cells highly immunoevasive [41] [42] [43] . Burkitt lymphoma is also characterised by the translocation of the gene encoding the oncogenic c-MYC protein 44 .
Nasopharyngeal carcinoma
EBV infection is associated with the majority of undifferentiated nasopharyngeal carcinoma (NPC) [45] [46] [47] . While rare in the Australian population, with an incidence of less than 1 in 100,000, EBVassociated NPC is endemic in regions of south-east Asia and North Africa. It reaches its highest prevalence in southern China with incidence rates of 15-50 cases per 100,000 within some communities 48 . An increased incidence of NPC is also evident in Australia in immigrant populations from these regions; however, this incidence is reduced in first generation Australians, indicative of the role both genetics and environment play in the development of NPC.
Similar to HL, EBV gene expression in malignant NPC cells is
restricted to EBNA1 and LMP1&2. Current treatment options for NPC typically involve surgical intervention, radiotherapy and/or chemotherapy 49 . Standard treatment options have seen response rates in primary disease improve to greater than 90%. Despite this, a significant proportion of patients, particularly those who initially present with late stage disease, will relapse, which often leads to distance metastases that are refractory to conventional therapy 49 .
EBV-targeted treatment options are therefore in development as adjunct approaches to current radio/chemotherapeutic regimes.
While some strategies focus on the induction of lytic viral reactivation as a potential mechanism of enhancing cellular immunity and inducing lysis of malignant cells, the majority of these approaches focus on using EBV-specific immunotherapy to treat NPC 33 ( Table 1) . Augmentation of cellular immunity to EBNA1 and the LMP antigens have emerged as potential adjunct or alternative approach to chemo/radiotherapy. A number of phase I clinical studies treating NPC with a range of immunotherapeutic strategies have provided evidence that these approaches are safe and might have some clinical benefit, particularly in patients with locoregional disease 33, 50 . Current efforts are being placed on validating these observations in larger cohorts of patients.
Other EBV-associated malignancies
EBV-infection has also been associated with a number of other In Focus characterised predominantly by the expression of EBNA1 and LMP2 52 (Table 1) . Despite this, due to the lack of an in vitro model, the role EBV and these latent antigens play in the tumorigenesis of NK/T cell lymphomas is not clear.
The EBV-associated lymphoepithelial-like carcinomas share features with NPC but are found in a range of other anatomical sites, including the stomach 53, 54 . These cancers also show a distinct geographical distribution and are endemic in regions of Asia and indigenous communities in America, further evidence for the influence of environment and genetics on the incidence of EBVassociated carcinoma. EBV-infection is also associated with a small percentage of non-lymphoepithelial-like gastric carcinoma cases 55 .
While the incidence of gastric carcinoma has reduced significantly in most developed countries, the incidence remains high in developing countries and in some developed countries, including Japan and Korea 56 . EBV infection in gastric carcinoma cells is associated with a latency I/II gene expression profile, characterised by the expression of EBNA1 and in some instances LMP2A 57, 58 . Although no aetiological relationship has been established between EBV infection and the transformation of gastric carcinoma cells, it will be important to explore therapeutic options that specifically target EBV to improve clinical outcome 59 .
Concluding remarks
Over the past two decades considerable knowledge has been accumulated on EBV pathogenesis in different malignancies. This 
